HK1208907A1 - Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin - Google Patents

Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin

Info

Publication number
HK1208907A1
HK1208907A1 HK15109568.6A HK15109568A HK1208907A1 HK 1208907 A1 HK1208907 A1 HK 1208907A1 HK 15109568 A HK15109568 A HK 15109568A HK 1208907 A1 HK1208907 A1 HK 1208907A1
Authority
HK
Hong Kong
Prior art keywords
pharmacokinetics
measuring
liposomal curcumin
tetrahydrocurcumin
metabolite
Prior art date
Application number
HK15109568.6A
Other languages
English (en)
Chinese (zh)
Inventor
Lawrence Helson
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of HK1208907A1 publication Critical patent/HK1208907A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C07C45/86—Use of additives, e.g. for stabilisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK15109568.6A 2012-06-14 2015-09-29 Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin HK1208907A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659660P 2012-06-14 2012-06-14
PCT/US2013/045898 WO2013188767A1 (en) 2012-06-14 2013-06-14 Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
US13/918,112 US9170257B2 (en) 2012-06-14 2013-06-14 Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin

Publications (1)

Publication Number Publication Date
HK1208907A1 true HK1208907A1 (en) 2016-03-18

Family

ID=49756241

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109568.6A HK1208907A1 (en) 2012-06-14 2015-09-29 Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin

Country Status (7)

Country Link
US (2) US9170257B2 (xx)
EP (1) EP2861982A4 (xx)
JP (1) JP2015522810A (xx)
AU (1) AU2013274105A1 (xx)
CA (1) CA2875094C (xx)
HK (1) HK1208907A1 (xx)
WO (1) WO2013188767A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393198B2 (en) 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
US8753674B2 (en) 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
CA2882978A1 (en) 2012-08-31 2014-03-06 University Of North Texas Health Science Center Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapy
WO2015095576A1 (en) 2013-12-18 2015-06-25 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
ES2942132T3 (es) 2014-06-03 2023-05-30 Signpath Pharma Inc Efecto protector de DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG y LYSOPC frente a fármacos que provocan canalopatías
WO2017021974A2 (en) * 2015-08-31 2017-02-09 Laila Pharmaceuticals Pvt. Ltd. Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts
CA2940470C (en) * 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
KR102181659B1 (ko) 2016-04-27 2020-11-24 사인패스 파마 인코포레이티드 약물 유발된 방실 차단의 방지
US20190224325A1 (en) * 2016-06-29 2019-07-25 Therabiopharma Inc. Drug composition for parenteral administration
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
CA3234239A1 (en) * 2018-06-13 2019-12-19 Texas Tech University System Modified tetracycline for treatment of alcohol use disorder, pain and other disorders involving potential inflammatory processes
WO2020175703A1 (ja) * 2019-02-28 2020-09-03 株式会社日本触媒 化粧料用水性分散体、化粧料組成物、及び化粧料の製造方法
JP2022551967A (ja) * 2019-10-15 2022-12-14 サミ－サビンサ グループ リミテッド クルクミノイド組成物および肺線維症の管理におけるその治療能力
CN114028362A (zh) * 2021-12-08 2022-02-11 晨光生物科技集团股份有限公司 一种高稳定性姜黄素缓释胶囊及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307117A (en) * 1980-03-27 1981-12-22 General Foods Corporation Stabilized curcumin colorant
US5679864A (en) 1995-11-03 1997-10-21 Gene Print Inc. Process for the synthesis of curcumin-related compounds
JP3272256B2 (ja) * 1997-01-17 2002-04-08 丸善製薬株式会社 クルクミノイドの安定化法および安定化クルクミノイド組成物
IL147185A0 (en) * 2001-12-19 2002-08-14 Lattstein Ora A method for the detection of compounds comprising methylenedioxyphenyl and a testing kit for the same
US7060733B2 (en) 2002-08-15 2006-06-13 The Regents Of The University Of California Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US7067159B2 (en) 2003-12-05 2006-06-27 New Chapter, Inc. Methods for treating prostate cancer with herbal compositions
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
DK1890546T3 (en) 2005-05-30 2019-03-11 Benny Antony Process for improving the bioavailability of curcumin
WO2007103435A2 (en) * 2006-03-06 2007-09-13 The Regents Of The University Of California Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
BRPI0812682A2 (pt) * 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US20120003177A1 (en) * 2008-09-17 2012-01-05 Youqing Shen Curcumin-containing polymers and water-soluble curcumin derivatives as prodrugs of prodrug carriers

Also Published As

Publication number Publication date
EP2861982A1 (en) 2015-04-22
WO2013188767A1 (en) 2013-12-19
US20150377894A1 (en) 2015-12-31
AU2013274105A1 (en) 2014-12-18
EP2861982A4 (en) 2016-02-17
JP2015522810A (ja) 2015-08-06
US20130337488A1 (en) 2013-12-19
CA2875094C (en) 2017-02-28
US9170257B2 (en) 2015-10-27
WO2013188767A8 (en) 2014-02-13
CA2875094A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
HK1208907A1 (en) Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
HK1216780A1 (zh) 對種或多種材料進行測量的系統及方法
HK1202329A1 (en) Temperature measurement system and method
HK1204648A1 (en) Methods and devices for detection and measurement of analytes
EP2852813A4 (en) SYSTEM AND METHOD FOR DOSE MEASUREMENT
EP2933599A4 (en) METHOD AND DEVICE FOR SHIFT MEASUREMENT
EP2779907A4 (en) SYSTEM AND METHOD FOR MEDICAL MEASUREMENT
EP2839296A4 (en) METHOD FOR DETECTING AND QUANTIFYING ANALYTES USING THREE DIMENSIONAL PAPER BASED DEVICES
PL2844146T3 (pl) Układ i sposób pomiaru uwagi
SG11201504790SA (en) Method and system for the examination of a sample by means of thermography
EP2802738A4 (en) SYSTEM AND METHOD FOR IMPROVED CUTTING MEASUREMENTS
SG11201408288PA (en) A system and method for measuring the crowdedness of people at a place
HK1207904A1 (en) Improved analyte measurement technique and system
EP2901145A4 (en) EMULSION MEASUREMENT AND PROFILING SYSTEM AND METHOD
GB2504822B (en) Range measurement apparatus and range measurement method
EP2869764C0 (en) SYSTEM AND METHOD FOR MEASURING BLOOD PARAMETERS
EP2926604A4 (en) METHOD AND SYSTEM FOR MEASURING MULTICHANNEL SENSOR
PL2719475T3 (pl) Układ pomiarowy oraz sposób pomiaru kąta
HK1213072A1 (zh) 在銷售點進行實時折扣的方法及系統
EP2902743A4 (en) DEVICE AND METHOD FOR MEASURING DISTANCES OF MULTIPLE SUBJECTS
EP2839771A4 (en) MEANS FOR MEASURING A COLOR DISPLAY FUNCTION AND SYSTEM FOR MEASURING A COLOR DISPLAY FUNCTION
EP2840958A4 (en) SHIFTING COMPENSATION METHODS FOR SUBSTANCE MEASUREMENTS TO BE ANALYZED, AND DEVICES THEREOF
EP2843694A4 (en) SYSTEM FOR MEASURING CAPACITANCE-VOLTAGE (CV) CHARACTERISTICS AND METHOD FOR MEASURING CV CHARACTERISTICS
ZA201406032B (en) Resistance measurement system and method of using the same
EP2875326A4 (en) SYSTEM AND METHOD FOR TORQUE MEASUREMENT